Brian S Posner
CIK 1372455 · last filed 2026-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.23M
Companies
7
Total Filings
80
Lifetime Open-Market Net
-$5.72M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYN | Director | 24,500 | $25.90 | $634.5K | $274.8K | 8 | 2026-06-09 |
| ACGLO | Director | 0 | $19.50 | $0 | $208.3K | 21 | 2026-06-04 |
| BIIB | Director | 8,175 | $205.61 | $1.68M | -$6.74M | 26 | 2021-07-02 |
| Bioverativ Inc. (BIVV) Delisted | Director | 0 | — | — | $166.9K | 7 | 2018-03-08 |
| ACGL | Director | 18,000 | $106.48 | $1.92M | $316.4K | 13 | 2018-01-02 |
| BG Medicine, Inc. (BGMD) Delisted | Director | 5,000 | — | — | $52.0K | 4 | 2013-06-14 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | — | — | — | $0 | 1 | 2011-08-24 |
Recent Filings · Page 5 of 8
80 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-09-19 | ACGL | Disp (D) | −4,659 | -$116.5K | EDGAR |
| 2017-08-10 | Bioverativ Inc. (BIVV) Delisted | Buy (P) | +1,000 | $59.2K | EDGAR |
| 2017-06-12 | BIIB | Sell (S) | −1,084 | -$277.8K | EDGAR |
| 2017-06-09 | BIIB | Grant (A) | +1,055 | $0 | EDGAR |
| 2017-05-24 | Bioverativ Inc. (BIVV) Delisted | Buy (P) | +2,000 | $107.7K | EDGAR |
| 2017-05-05 | ACGL | Grant (A) | +2,057 | $0 | EDGAR |
| 2017-04-17 | Bioverativ Inc. (BIVV) Delisted | Grant (A) | +1,056 | $60.0K | EDGAR |
| 2017-03-27 | Bioverativ Inc. (BIVV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-16 | Bioverativ Inc. (BIVV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-11-21 | ACGL | Buy (P) | +6,000 | $131.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.